Herantis Pharma

Executive Summary

Herantis Pharma is a clinical-stage biotechnology company headquartered in Helsinki, Finland, dedicated to developing disease-modifying therapies for neurodegenerative diseases. Its lead candidate, HER-096, is a small synthetic peptidomimetic molecule designed for Parkinson's disease, with a novel mechanism targeting neuroinflammation and protein aggregation. The company's approach aims to address the significant unmet medical need in Parkinson's, where current treatments only manage symptoms. Herantis is currently advancing HER-096 through Phase 1 clinical trials, with a focus on safety, tolerability, and pharmacokinetics. The company's strong scientific foundation and focus on disease modification position it as a potential leader in the neurodegenerative space, though it remains early-stage with limited public data. Key upcoming milestones include the completion of the Phase 1 trial for HER-096, which is expected to provide initial proof-of-concept data. A successful readout could pave the way for Phase 2 studies and potential partnerships. Herantis also continues to explore additional indications for its platform technology. The company's progress will be closely watched by investors given the high unmet need and the potential for disease-modifying therapies in Parkinson's. However, the risk profile remains elevated due to the early stage and typical clinical development uncertainties.

Upcoming Catalysts (preview)

• Q3 2026Phase 1 clinical data readout for HER-096 in Parkinson's disease70% success
• Q1 2027Initiation of Phase 2 trial for HER-09640% success
• TBDPotential partnering or licensing agreement for HER-09630% success